本文仅供信息分享,不构成用药或治疗或投资推荐。因编辑水平有限,如有错误或不是最新信息感谢指出!7月15日,中国生物制药宣布,透过全资附属公司正大制药投资以不超过9.5092亿美元收购礼新医药95.09%股权。扣除礼新医药集团于交割日的估计现金及银行存款约4.5亿美元,实际净付款额约为5.009亿美元。交易完成后,礼新医药将成为中国生物制药的间接全资附属公司。礼新医药是一家专注于肿瘤免疫及肿瘤微环境...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.